Cricopharyngeal Botox injection: Indications and technique

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 14, Issue 6, 2006, Pages 431-436

  Moerman, Mieke B J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b AZ Jan Palfijn Ghent ^*  (Belgium)

Author keywords

Botox; Botulinum toxin; Cricopharyngeal muscle; Oropharyngeal dysphagia; Upper esophageal sphincter

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ASPIRATION; CHOLANGIOGRAPHY; CRICOPHARYNGEUS MUSCLE; DYSPHAGIA; HUMAN; LITERATURE; MYOTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URINE RETENTION;

BOTULINUM TOXIN TYPE A; DEGLUTITION DISORDERS; ESOPHAGEAL SPHINCTER, UPPER; HUMANS; INJECTIONS, INTRAMUSCULAR; NEUROMUSCULAR AGENTS;

EID: 33750965616     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e328010b85b     Document Type: Review

References (35)

1. Poulain B, Humeau Y. Le mode d'action des neurotoxins botuliques: aspects pathologiques, cellulaires et moléculaires [Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect]. Annales de réadaptation et de médecine physique 2003; 46:265-275
2. Jankovic J, Schwartz K. Response and immunoresistance to botulinum injections. Neurology 1995; 45:1743-1746
3. Davletov B, Bajohrs M, Binz T. Beyond botox: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci 2005; 28:446-452. This manuscript highlights the working mechanism of the seven botulinum toxin types, discussing the differences in clinical and future applications.
4. Sutcliff RP, Sandiford NA, Khawaja HT. From frown lines to fissures: therapeutic uses for botulinum toxin. Int J Surg 2005; 3:141-146
5. Jost WH. Other indications of botulinum toxin therapy. Eur J Neurol 2006; 13:65-69
6. Marchese-Ragona R, Marioni G, Restivo DA, Staffieri A. Solving dysphagia due to cricopharyngeal muscle dysfunction with botulinum toxin. Eur Arch Otorhinolaryngol 2005; 262:250-251. This paper emphasizes the advantages of percutaneous injection under EMG guidance. Manometry does not seem essential in the assessment in contradistinction to videofluoroscopy.
7. •] in which the endoscopic injection technique is advocated and the importance of videofluoroscopy is discussed.
8. Halum SL, Butler SG, Koufman JA. Treatment of globus by upper esophageal sphincter injection with botulinum A toxin. Ear Nose Throat J 2005; 84:74
9. Restivo DA, Marchese-Ragona R. Botulinum toxin treatment for oropharyngeal dysphagia due to tetanus. J Neurol 2006; 253:388-389. This article describes a new application of botulinum toxin: treating a spastic paralysis caused by a similar neurotoxin.
10. Schneider I, Pototschnig C, Thumfart W, Eckel H. Treatment of dysfunction of the cricopharyngeal muscle with botulinum toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol 1994; 103:31-35
11. Crary M, Glowasky A. Using botulinum toxin A to improve speech and swallowing following total laryngectomy. Arch Otolaryngol Head Neck Surg 1996; 122:760-763
12. Blitzer A, Brin M. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg 1997; 116:328-330
13. Atkinson SI, Rees J. Botulinum toxin for cricopharyngeal dysphagia: case reports of CT-guided injection. J Otolaryngol 1997; 26:273-276
14. Ahsan SF, Meleca RJ, Dworkin JP. Botulinum toxin injection of the cricopharyngeal muscle for the treatment of dysphagia. Otolaryngol Head Neck Surg 2000; 122:691-695
15. Alberty J, Oelerich M, Ludwig K, et al. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Laryngoscope 2000; 110:1151-1156
16. Restivo D, Marchese-Ragona R, Staffieri A, De Grandis D. Successful botulinum toxin treatment of dysphagia in oculopharyngeal muscular dystrophy. Gastroenterology 2000; 119:1416
17. Haapaniemi J, Laurikainen E, Pulkkinen J, Marttila R. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia 2001; 16:171-175
18. Restivo DA, Giuffrida S, Marchese-Ragona R, Falsaperla R. Successful botulinum toxin treatment of dysphagia in a young child with nemaline myopathy. Dysphagia 2001; 16:228-229
19. Shaw G, Searl J. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia 2001; 16:161-167
20. Moerman M, Callier Y, Dick C, Vermeersch H. Botulinum toxin for dysphagia due to cricopharyngeal dysfunction. Eur Arch Otorhinolaryngol 2002; 259:1-3
21. Parameswaran M, Soliman A. Endoscopic botulinum toxin injection for cricopharyngeal dysphagia. Ann Otol Rhinol Laryngol 2002; 111:871-874
22. Restivo D, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N Engl J Med 2002; 346:1174-1175
23. Chiu MJ, Chang YC, Hsiao TY. Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: case report and literature review. Dysphagia 2004; 19:52-57
24. Zaninotto G, Marchese-Ragona R, Briani C, et al. The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia. J Gastrointest Surg 2004; 8:997-1006
25. Yoneda S, Shimazawa M, Kato M, et al. Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A. Eur J Pharmacol 2005; 508:223-229. This study is promising for future exploitation. It suggests an eventual alternative in cases of botulinum A resistance.
26. Mancini F, Sandrini G, Moglia A, et al. A randomized, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005; 26:26-31
27. Jost WH, Kohl A, Brinkman S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 2005; 112:905-913. BoNT/A free of complexing proteins seems comparable with Botox in terms of efficacy, time of onset, duration and tolerability.
28. Blitzer A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg 2005; 133:836-838. This paper has an important clinical relevancy calculating the conversion factor between BoNT/A and BoNT/B
29. Bigalke H, Dressler D. Botulinum toxin type B de novo therapy of cervical dystonia. J Neurol 2005; 252:904-907. The authors temper the use of BoNT/B as a first treatment, which illustrates the fact that BoNT/B must only be used after BoNT/A failure.
30. Aoki KR. Guyer Botulinum toxin type A and other botulinum toxin serpotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8:21-29
31. Cherington M. Botulism: update and review. Semin Neurol 2004; 24:155-163
32. Zwirner P, Schönweiler R. The dosage of botulinum toxin type B in adductor spasmodic dysphonia. HNO 2005; 53:166-173
33. Satila H, Kotamaki A, Koivikko M, Autti-Ramo I. Low- and high-dose botulinum toxin A treatment: a retrospective analysis. Pediatr Neurol 2006; 34:285-290
34. Thomas J, Siupsinskiene N. Frozen versus fresh reconstituted botox for laryngeal dystonia. Otolaryngol Head Neck Surg 2005; 133:59. This is a surprising report with great potential for clinical practice: refrozen and fresh botulinum toxin A are comparable in terms of efficacy and risk.
35. Périé S, Laccourreye L, Flahault A, et al. Role of videoendoscopy in assessment of pharyngeal function in oropharyngeal dysphagia: comparison with videofluoroscopy and manometry. Laryngoscope 1998; 108:1712-1716